Chemical Structure (Alendronate 01)
Alendronate
Product Images NDC 50090-3593
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 50090-3593). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Alendronate 02)
This appears to be a graph or chart showing the cumulative incidence of something over time (in months) with two treatments: Placebo and Alondronate Sodium. The percentage shown is 10. Unfortunately, without additional context or information, it is difficult to determine what exactly the graph represents.*
Figure 2 (Alendronate 03)
Figure 3 (Alendronate 04)
Figure 4 (Alendronate 05)
This appears to be a table with headings related to changes in BMD (Bone Mineral Density) from baseline in a study over 2 and 3 years, comparing Alendronate Sodium 5mg/day and Placebo. The table contains data related to Lumbar Spine, Femoral Trochanter, Total Neck and Body.*
Figure 5 (Alendronate 06)
Figure 6 (Alendronate 07)
This is a table that shows the mean percentage change in serum alkaline phosphatase from baseline for different treatments in a study conducted over the course of three months. The treatments include a placebo, etidronate 400 mg/day, and two doses of alendronate sodium (40 mg/day) from two different studies - one conducted internationally and another one conducted in the United States.*
Label Image (Lbl500903593)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
